Michele Sandre is graduated in Pharmaceutical Biotechnology in 2018 at the University of Padua, carrying out a thesis at the Biochemistry Department of the University of Lausanne, entitled 'Inhibition of BET proteins in cancer-associated fibroblasts as a potential CAF-based cancer theraphy '. During the period of the Master's Degree as a fellow he worked on various projects at the laboratory of the Facility of Proteomics and Peptide Synthesis of CRIBI (Biotechnology Center, UniPD). Currently, under the supervision of Prof. Angelo Antonini, he is pursuing a PhD at the PNC (Padua Neuroscience Center) and the Department of Neuroscince sponsored by the pharmaceutical company Lundbeck. The research aims to define biomarkers with the aim of selecting patients for precision immunotherapy in synucleinopathies.

Dr. Laura Santambrogio received her Ph.D. from Padua University and trained as a post-doctoral fellow at NYU and Harvard Medical School with Jack Strominger. She was recruited at Albert Einstein College of Medicine with an Irene Diamond Professorship in Immunology and recently moved to Weill Cornell where she held the position of Associate Director of Precision Immunology in the Englander Institute of Precision Medicine, Professor of Radiation Oncology, Physiology and Biophysics. Current efforts in her laboratory are focused on the mechanisms of antigen processing and presentation, peptide binding to MHC class II molecules, and the overall role of dendritic cells in innate and adaptive immune responses. She is tackling these questions using an integrated approach that combines cell biology, biochemistry, and biophysics. Important questions addressed by her laboratory relates to the different cellular pathways utilized for antigen processing and presentation which include autophagy, endosomal processing, and surface MHC II loading. Additionally, she is interested in understanding how changes in the cellular transcriptome and metabolome translate in the plasticity of the MHC II immunopeptidome.

1993 – 1999 Tokyo Medical and Dental University, Faculty of Medicine 1999 – 2000 Resident, Tokyo Medical and Dental University, Medical Hospital 2000 – 2001 Resident, Yokosuka Kyosai Hospital 2001 – 2002 Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Medical Hospital Department of Neurology, Saitama Rehabilitation Center 2002 – 2004 Department of Neurology, Asahi General Hospital 2004 – 2005 Department of Neurology, Kanto Central Hospital 2005 – 2009 Graduate Student, Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University 2009 – 2012 Department of Neurology, Saitama Rehabilitation Center 2012 – 2014 Department of Neuroscience, Mayo Clinic, Jacksonville (Prof. Petrucelli) 2014 – 2016 Department of Neurology, Nitobe Memorial Nakano General Hospital 2016 – 2019 Research fellow, Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Department of Neurology and Neurological Science, Tokyo Medical and Dental University 2019 Dec – present Deputy Team Leader, Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Department of Neurology and Neurological Science, Tokyo Medical and Dental University

Mike Sasner got his BA in Biology and Biochemistry from Colby College and his PhD in Physiology & Neurobiology from the University of Connecticut. His post-doc was in NICHD, NIH working an activity-dependent gene regulation. He has been Manager of the Technical Information Science group and Associate Director of the Genetic Resource Science at the Jackson Lab in Bar Harbor, Maine. He is currently a Senior Research Scientist at the Jackson Lab, and Center Manager for the NIA-funded MODEL-AD program.

Carlos A. Saura obtained his Ph.D. in Chemistry/Biochemistry and Molecular Biology from the University of Barcelona (Spain). Dr. C. Saura performed postdoctoral training at Prof. G. Thinakaran´s lab at the Department of Pathology-Johns Hopkins University School of Medicine and Department of Neurobiology -University of Chicago. Dr. Saura investigated the biology of autosomal-dominant familial Alzheimer’s disease-linked mutations. Dr. Saura was then appointed Instructor Professor at the Center for Neurologic Diseases, Brigham and Women’s Hospital/Harvard Medical School (Boston). Under the mentoring of Prof. J. Shen, Dr. Saura investigated the cellular and molecular mechanisms underlying memory and neurodegeneration in novel transgenic and knockout mouse models of Alzheimer’s disease. In 2004, he was appointed Ramón y Cajal Research Professor at the Universitat Autònoma de Barcelona (Spain). Dr. C. Saura is currently Associate Professor at the Department of Biochemistry and Molecular Biology and Institut de Neurociències of UAB, and member of the Spanish National Neurodegeneration network CIBERNED. Dr. Saura has published more than 60 peer-reviewed articles on molecular and cellular mechanisms of brain physiology and pathology. He has leaded several national and international research projects and is an active collaborator of several national and international funding agencies and scientific journals.

Dr Sharon Savage is a Clinical Neuropsychologist and lecturer in the School of Psychological Sciences at the University of Newcastle, Australia. Fascinated by the brain and its disorders, and keen to further her clinical experience working with people diagnosed with neurodegenerative conditions, she joined the Frontotemporal Dementia Research Group at Neuroscience Research Australia as a research neuropsychologist (2007-2014), where she contributed to a number of important studies into Frontotemporal dementia, motor neurone disease, and Parkinson's Plus syndromes (Corticobasal Syndrome and Progressive Supranuclear Palsy). Over 2011 to 2014, Sharon completed her PhD, investigating assessment and cognitive interventions for people with Primary Progressive Aphasia. Since then she has been developing eHealth applications to assist diagnosis and treatment in people with language and memory difficulties. Over her career to-date, Sharon has authored over 50 journal articles and presented her work at multiple major international and national conferences. Her most recent research explores spoken language impairments within a range of neurodegenerative conditions. https://www.newcastle.edu.au/profile/sharon-savage

MD, Neurologist, FEBN, PhD candidate at Alzheimer Center Amsterdam UMC. Research topics: frontotemporal dementia, clinico-pathological correlations, psychiatric symptoms, neuropathology.

Sophia Schedin Weiss, PhD, is an Associate Professor at the Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. Sophia Schedin Weiss studied chemistry at Stockholm University and received her PhD in biochemistry at Stockholm University in 1998. She did a postdoc at the Swedish University for Agricultural Sciences, Uppsala, specializing in protein-protein and protein-glycan interactions. She obtained her docentur in medical biochemistry at Uppsala University in 2008. Since 2010 she is enrolled in research related to Alzheimer disease at Karolinska Institutet, where she specializes in in super-resolution microscopy. Her main focus is to study the subcellular localization of the components of the amyloid precursor protein processing machinery in neurons using STimulated Emission Depletion (STED) microscopy and single molecule localization microscopy techniques.

I'm a joint MD-PhD candidate between the Neuroimaging Laboratory at Federal University of Rio Grande do Sul (UFRGS; Brazil) and the Clinical Neurochemistry Laboratory (University of Gothenburg, Sweden).

Prof. dr. Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD in 1993. Clinical residencies in neurosurgery and neurology supported his academic development. He is Professor of Cognitive Neurology and founder of the Alzheimer Center at Amsterdam University Medical Centers. Currently his main activity is managing partner of the LSP Dementia Fund, that he started in 2020. He has been the (inter)national PI for over 35 studies, including phase 1-3 multicenter clinical trials. He supervised >75 PhD theses since 2000. He founded the Dutch national plan against dementia and served as chair of the board. He is co-editor-in-chief of Alzheimer’s Research & Therapy and co-leads various EU projects. He authored over 1100 peer reviewed papers and > 75 book chapters and co-edited several major text books. He is member of the Royal Dutch Academy of Arts and Sciences (KNAW) since 2011. In 2016 he was awarded the European Grand Prix for Alzheimer’s Research. In 2020 he was Knighted in the Order of the Netherlands Lion by the King of the Netherlands. In 2021 he was elected honorary member of the European Academy of Neurology and was appointed chair of the World Dementia Council.

Irene Schilcher is Deputy Head of in vitro research and Project Manager at QPS Austria, department neuropharmacology. QPS Austria is a contract research organization, and the neuropharmacology department focusses on in vitro and in vivo research of neurodegenerative and rare diseases. At QPS Austria, Irene started her career in 2018 as a Preclinical Research Assistant and was quickly promoted to her current position. Irene brings to this position a well-established background in biochemistry and molecular medicine with a Master’s and PhD from the Karl-Franzens University and Medical University of Graz, Austria, respectively. The success of her research efforts can be measured by already nine peer-reviewed scientific publications in the field of Atherosclerosis, Alzheimer’s disease, and Gaucher disease. Furthermore, Irene presented several posters at international scientific neurodegenerative disease-related conferences and two oral presentations at the Austrian Atherosclerosis Society meeting 2017 in Austria and the International Conference on Alzheimer’s and Parkinson’s diseases (AD/PD), 2019 in Portugal. Currently, Irene’s research focusses on protein aggregation in in vitro and in vivo models of neurodegenerative diseases like Tau aggregation in seeding experiments and TDP-43 aggregation in amyotrophic lateral sclerosis.